Speakers

Antoine Papiernik

Antoine Papiernik

Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Addex, Orexo, NovusPharma (then sold to CTI), Movetis (then sold to Shire) and Stentys, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis). He has also invested in and is a board member of private companies MD Start, CoAxia, EOS, Mainstay and ReCor. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania.

For 2012 and 2011, Antoine has been recognized on the Forbes “Midas List” of the top dealmakers in life-science and high-tech venture capital. Antoine is one of the only Europeans on the list, and one of the few life-science investors as well.


Oliver Murphy

Oliver Murphy

Oliver Murphy Partner Transaction Advisory ServicesOliver is a graduate of the University of Manchester in Economics and Government. He speaks fluent Polish. Oliver has has a wide range of corporate finance, due diligence and restructuring and integration experience within both the UK and Poland and specialises in cross-border transaction support engagements comprising large multi-disciplinary, multinational teams.


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a bioentrepreneur who has worked in the industry for approaching two decades. Roland has held a number of operational roles including most recently Chief Executive Officer and a founder of Lectus Therapeutics Limited (investor exit via asset sale to UCB in Q4, 2011), Chief Executive Officer and co-founder of Sense Proteomic Limited (trade sale to Procognia Limited in Q1, 2003). In the mid 1990s Roland worked with Oxford Molecular PLC on their cornerstone deal he negotiated with Yamanouchi Pharmaceutical Co., Ltd. During his career Roland has gained considerable transactional experience ranging from company sale, purchase, financing and in- and out-licensing and commercialisation of technology. In the past Roland ran a Research Groups at the University of Oxford and University of Bristol where subsequently he was a Visiting Industrial Professor. He has published and patented in the field of ion channel physiology and pharmacology. Roland has served on the boards of a number of companies including the Bio-Industry Association in the UK. He remains a director of Lectus Therapeutics Limited and is presently non-executive director of London Genetics Limited which operates in the personalised medicine space, Chief Strategy Officer of BTM Mazowsze Sp. z o. o. a company set up to commercialize innovation emerging from the leading life science research institutions in Warsaw.


Leszek Grabarczyk

Leszek Grabarczyk

Leszek Grabarczyk Since April 2011 Deputy Director of the National Centre for Research and Development – reshaped governmental agency playing the main role in funding applied research and supporting commercialisation of research results. January 2009 – March 2011: director of the Department for Research Applications and Innovation, Ministry of Science and Higher Education, Warsaw (main responsibilities: funding of projects and infrastructures for R&D within operational programmes Innovative Economy and Human Capital, elaboration and implementation of other programmes supporting innovation, coordination and monitoring of activities of other institutions engaged in support of R&D and innovation). July 2007 – December 2008: deputy director of the National Centre for Research and Development – NCRD (governmental agency funding R&D, established 1 July 2007). 2004-2007: in the Polish Ministry of Science and Higher Education, Department of Science Strategy and Development; engaged inter alia in preparation of legal framework for NCRD, operational programmes Innovative Economy and Human Capital, elaboration and implementation of the largest governmental programme funding R&D and innovative activities – “Technology Initiative”. Graduated from the National School of Public Administration, Warsaw.


Pawel Przewiezlikowski

Pawel Przewiezlikowski

Pawel Przewiezlikowski, co-founded Selvita in 2007 and is the Chief Executive Officer of the company, responsible for strategic management, business and corporate development. He is also the Chief Executive of BioCentrum, Selvita’s daughter company. Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region as well as of the Malopolska Innovation Council. From 1994 to 2007 he worked at ComArch, a Polish information technology company. As a management board member since 1996, he was responsible for the divisions offering solutions for the pharmaceutical, banking, manufacturing and services industries and took part in the organic transformation of a university spin-off to the largest organically grown IT company in Central and Eastern Europe, employing over 2 700 people in 20 countries. During his time at ComArch in 1999-2000 he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. Mr. Przewiezlikowski holds an MBA from the joint program of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow.


John E. Milad

John E. Milad

John E. Milad has nearly 20 years’ experience in private equity, venture start-ups, corporate finance and the healthcare industry. He is an Investment Director of NBGI Ventures, a specialist medtech investment fund based in London. John serves on the boards of several portfolio companies in Europe and the US. He is also a member of the i4i selection panel of the NHS National Institute for Health Research and is an advisory board member of Connect Digital Health.His previous roles include founding the advisory boutique Insight Capital, serving as CFO at Nitec Pharma, being a Special Advisor to Atlas Venture and leading healthcare corporate finance transactions at Nomura International in London. He started his career as an investment banker at Lehman Brothers in New York, followed by private equity investment experience at Kirkland Investors. John is a graduate of the University of Chicago.


Mark Treherne

Mark Treherne

Mark has been actively involved in the biopharmaceutical industry for 25 years and was a co-founder and Chief Executive of Cambridge Drug Discovery Limited, leading the Company’s acquisition by BioFocus plc, where he then became a Commercial Director, driving significant growth of its profitable services business. Mark has now served on the Boards of 13 private and public biopharmaceutical companies and is currently on the Boards of Cyclofluidic, Domain Therapeutics, Population Genetics Technologies and Senexis. Dr Treherne has now helped raise more than £140 million for various biopharmaceutical businesses over the last decade. Mark was also formerly Chairman of ERBI Limited, which is a not-for-profit organisation that represents the biotechnology companies based around Cambridge in the East of England. Mark initially trained as a neuroscientist and electrophysiologist at Cambridge University. Mark joined the Life Science Investment Organisation as Chief Executive, following its formation by UK Trade and Investment.


Derek Jones

Derek Jones

Derek, as CEO of Babraham Bioscience Technologies, has brought a wealth of experience to the Babraham Research Campus arguably the UK’s most successful bio-incubator site. He has over 20 years’ in the pharmaceutical industry as both a scientist and in business and corporate development, with first-hand experience of establishing biomedical ventures. Initially a medicinal chemist with Merck, Derek moved into business and corporate development at Chiroscience, successfully negotiating several multi million pound licensing agreements. In 2000, he co-founded his first company, BioWisdom, an IT/Drug discovery company. Derek was appointed COO at DanioLabs in 2002, a therapeutics company using zebrafish as a model organism for drug discovery, where he grew the company from 4 to 34 employees and raised around £10 million for VC backed companies, before selling DanioLabs to Vastox, now Summit Plc, for £15 million in 2007. He has an MBA from the Judge Business School, and is a Chartered Director. Derek is also a member of the Cambridge Enterprise Investment Committee which invests in early stage opportunities arising from research at Cambridge University.


Kevin FitzGerald

Kevin FitzGerald

Kevin FitzGerald is a life-sciences entrepreneur with a strong track record in the commercial exploitation of novel biologics technologies. As CEO for F-star (a bi-specific antibody company) Kevin raised €23m in two investment rounds; the first co-led by Merck Serono Ventures and MP Healthcare Venture Management and the second led by SR One. While at F-star, Kevin also secured substantial commercial agreements with Merck Serono and with Boehringer Ingelheim (the latter deal being the 7th largest biotech-to-pharma deal of 2010). As a result, F-star was voted onto the Fierce15 list for 2011, the only European company to be included on that list. Prior to this, Kevin was founder and CEO of Isogenica (a therapeutic peptide company) where he secured deals with AZ, J&J, Amgen, Centocor, Pfizer, Wyeth, GE Healthcare and many others. Kevin has also served as Chief Operating Officer for Immune Targeting Systems (a T-cell vaccine company) and he was among the founding scientists of Cambridge Antibody Technology. Kevin studied for his PhD at the MRC Laboratory of Molecular Biology, Cambridge, in the laboratory of Sir Gregory Winter FRS and he was awarded an MBA with distinction from Aston Business School, Birmingham.


Marek Orłowski

Marek Orłowski

Dr. Orłowski was a Co-Founder of Nepentes SA, a manufacturer and supplier of pharmaceutical products. In his time with the company, he served as as its Sales, Marketing and R&D Vice President. At the time of the company’s establishment in 1991, he held the position of Marketing Director. In 1995, he took the position of Vice-President of the newly founded Nepentes Sp. z.o.o. (Ltd. Company) and ran the company until it went public and was sold to Sanofi-Aventis for about €106M in 2010. In August 2007, he became Vice-President of the Management Board of Nepentes S.A. and since September 2010, was a member of the Management Board. He was responsible for marketing, sales, portfolio creation, strategic development and R&D. He negotiated distribution contracts and coordinated product launches in the markets of Eastern Europe; from Russia, through Poland, to Romania. Today he is a board member and investor in various life-science projects in Poland, Canada and Israel.


Phil Gould

Phil Gould

Phil Gould is the CEO of Jadara Pharma Ltd – a business and technical consultancy set up to support the growth of emerging healthcare companies. Phil has a strong interest in working with small, start up life companies and the challenges that these companies face in the development of their businesses. His present work involves aspects of technical and IP due diligence, working with emerging companies on behalf of their investors, and supporting international R&D collaborations for a number of clients.

Phil graduated from Hull University with a degree in chemistry and then a PhD in physical chemistry and kinetics. He has a strong interest in drug discovery and development and has worked in the area for over 30 years for both major pharmaceutical companies such as GlaxoSmithKline and Pfizer, and also a number of biotechnology companies.

As an experienced life science based non-executive director, Phil has held board positions at Oratol Ltd, Lectus Therapeutics Ltd, Well Travelled Clinics and Bradford Pharmaceuticals Ltd, and is currently a non-executive director of RedX Pharma Ltd. At RedX Pharma, Phil also chairs the Scientific Advisory Boards in anti-infectives and oncology and is retained as a programmes advisor.

Phil also continues to work in the ‘not for profit’ healthcare sector, using his experience of previously being the Chief Business Officer for the Liverpool School of Tropical Medicine, developing its international R&D and big pharma collaborations, supported by the Bill and Melinda Gates Foundation, in the areas of neglected disease.


Barry Kenny

Barry Kenny

Barry has over 25 years research and management experience in the pharmaceutical and biotechnology industry and is currently Chief Business Officer at Heptares Therapeutics where he leads the Company’s licensing and business development activities. He was previously Vice President, Drug Discovery at Takeda Cambridge UK with overall responsibility for IND discovery. Prior to this, he was Commercial Director at Paradigm Therapeutics where he was responsible for several company transforming deals and was also instrumental in the subsequent acquisition of Paradigm by Takeda in 2007. Barry co-founded Cambridge Drug Discovery (CDD) in 1997, and was Director of Business Development for Biofocus following its merger with CDD in 2001, establishing a wide range of international deals and collaborations. Before this, he was at Pfizer Central Research and was responsible for the successful discovery and progression of several drug candidates into clinical development. He also spent eight years at Syntex Research Scotland, where he completed his PhD and post-doctoral studies.


David Tapolczay

David Tapolczay

Dr David Tapolczay has 28 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition David was VP of Pharmaceutical Sciences with responsibility for over 230 scientists. On leaving Millennium David was a founder of Pharmorphix Ltd which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the start up of 5 companies all of which are still trading and one of which has been AIM listed. He was most recently VP of Technology Development for GSK pharmaceuticals and is currently the Chief Executive Officer of the Medical Research Council Technology Group (MRCT).

David has an international reputation in the pharmaceutical industry as well as an outstanding academic track record with a considerable number of patents and publications. He was a visiting Professor at Sussex University and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC. In addition he is a non executive director for several biotech companies.


Sven Rohmann

Sven Rohmann

Sven Rohmann, MD, PhD, MBA

General Manager Europe & Managing Director Digital Health

Burrill & Company and Burrill Securities

Dr. Rohmann has a scientific, academic background in clinical medicine and basic research. He spent 10 years at Merck Serono, which provided him with a strong foothold in the pharmaceutical industry. His career exposed him to pre-clinical, clinical development as well as marketing, business and corporate development. During his tenure at Merck he was involved in the successful licensing of Erbitux from ImClone and the establishment of Merck Oncology. Dr. Rohmann joined Burrill & Company in 2010.

Prior to joining Burrill & Company, Dr. Rohmann worked as Venture Capital Fund Manager for Novartis Pharma AG, and as Managing Partner at Nextech Venture, both Switzerland. In addition, Dr. Rohmann served as CEO of two European biotech start-ups and gained board experience at three SME’s in Germany.

Dr. Rohmann’s unique blend of scientific, pharma/biotech and venture knowledge, an extensive network of contacts among health care providers as well as academic and government research administrators, a thorough knowledge of European research and regulatory policies, and a significant experience in global as well as European partnering significantly extends the investment reach of Burrill & Company towards Europe.

Dr. Rohmann received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University, Rotterdam, Netherlands.


Kevin Johnson

Kevin Johnson

Kevin Johnson is a Partner at Index Ventures working out of the London office.Prior to that he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio. Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer.Kevin led both the development of CAT’s platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development. Two of these are now marketed, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK). He was also part of the management team that floated CAT on the London Stock Exchange (main market).Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.


Maria Bednarek

Maria Bednarek

Maria BednarekMaria is Principal Scientist, Peptide Platform, at MedImmune Ltd, UK with over 30 years of research and management experience in academia and pharma R&D. She has strong interest in the discovery and development of drugs targeting metabolic diseases. After 20 years at Merck Research Laboratories (USA) she joined MedImmune, the global biologics R&D unit of AstraZeneca, in 2009 where she has established and now leads the therapeutic peptide discovery team.A chemistry graduate from the University of Lodz and Gdansk (PhD), Maria subsequently conducted research at Case Western Reserve University and Harvard Medical School. She is an internationally recognized scientist with a considerable publication and patent record. Maria is an active member of the Council of the American Peptide Society and organizer of scientific conferences.


Dr. Ralf Emmerich

Dr. Ralf Emmerich

Dr. Ralf Emmerich is Investment Manager at the European Investment Fund, which he joined in 2011. At EIF, he is mainly focussing on fund-of-funds investments under the ERP-EIF Dachfonds mandate into Life Sciences VC funds and is as such representing EIF as advisory/supervisory board member in many VC funds. Prior to EIF, Ralf Emmerich spent six years as managing consultant at Capgemini Consulting, where he led strategic consulting projects for pharma companies and public research institutions in the areas of strategy development, merger&acquisition, post-merger integration, technology transfer and organisation & process development. Before this, he worked for five years as investment manager at Aurelia Private Equity responsible for Life Sciences investments and as equity analyst at Concord Effekten, an investment bank in Frankfurt. Ralf Emmerich received his Ph.D. at the Swiss Federal Institute of Technology Zurich and studied biochemistry at University of Bayreuth and University VII, Paris, as well as economics at the academic Business School Lahr.


Annita Westenbroek

Annita Westenbroek

Since 1 March 2010 Annita Westenbroek is director of the Dutch Biorefinery Cluster, a cooperation between the Dutch bio-based industries, and since 1 October 2011 she is also employed as director innovations at the Royal Association of Dutch Paper and Board Industries.

Currently Annita Westenbroek is Coordinator Programming in the preparation of BRIDGE, the Biobased Industries PPP under Horizon 2020.Annita studied Chemical Engineering and received her PhD on the basis of a project towards refining of paper making fibres. She has been employed for 11 years at Wageningen UR, of which the last years being responsible for coordination of the research group focusing towards the pulp & paper industry. From 2006 until 2011 she was program manager at the Centre of Competence Paper and Board. At national level she coordinated the collective research on fibre raw materials for the Dutch paper and board industry and the Program ‘Biorefinery’ of the Dutch Energy Transition in the Paper Chain.


Mike Romanos

Mike Romanos

Mike Romanos is CEO and founder of Crescendo Biologics Ltd, a VC-backed Cambridge based company that has developed an innovative transgenic platform for generating human single domain antibody therapeutics. He has 25 years’ biotech and pharmaceutical industry experience in biologic and NCE drug discovery across several therapeutic areas, starting with Wellcome Biotech, an early pioneer in UK biotechnology, in the 1980s.Previous to his current role, Mike held leadership positions for over 10 years in GlaxoSmithKline R&D, building and managing global Discovery organisations that made a major impact in targets, technology and pipeline projects. In particular, Mike played a key role in establishing GSK’s antibody lead discovery capability which generated a pipeline of in-house monoclonal antibodies, several of which are in clinical development.Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and undertook postdoctoral research in Virology at the MRC’s National Institute for Medical Research and in Yeast Biotechnology at Leicester Biocentre. He is currently a panel member of the MRC’s Developmental Pathway Funding Scheme, which funds translational studies through preclinical and early clinical development, and a Fellow of the Society of Biology.


Mark Bushfield

Mark Bushfield

Mark is a biologist with over 20 years of research and management experience in Pharma, Biotechnology and Lifesciences R&D. After completing a PhD in Cellular Signalling, Mark spent 4 years studying signal transduction in New York and Glasgow before joining Pfizer in 1990. He took on increasing responsibility for technology and therapeutic area research over a 7 year period at Pfizer. In 1997, Mark co-founded Cambridge Drug Discovery Limited to provide high-throughput lead discovery services to major Pharma and Biotechnology companies. CDD built a portfolio of IP and collaborations and was sold to BioFocus in 2001 for £28 million. After a 2-year period as Biology Director of BioFocus, Mark was appointed Research Director of Celltech and then VP of Research following the acquisition of Celltech by UCB in 2004, with discovery research responsibility spanning 4 research sites in the UK, Belgium and Germany. Mark joined Abcam in November 2008 as Scientific Director and leads product development and manufacturing and scientific business development.


Johannes Zanzinger

Johannes Zanzinger

Global Head, CardioMetabolic Business Development and Licensing

Boehringer Ingelheim Pharma GmbH & Co KGJohannes leads Global Business Development and Licensing for Cardiometabolic Diseases within the Therapeutic Alliances & Strategic Partnerships (TASP) function at Boehringer Ingelheim. In addition, he acts as an adjunct Professor of Physiology at the University of Ulm, Germany.Johannes gained science and R&D management experience across multiple disease areas in academia and industry, at Pfizer (UK) and Boehringer Ingelheim before taking on his role in Business Development & Licensing in the same company in 2006.Johannes Zanzinger was trained in Animal Sciences and Biology at the University of Hohenheim in Germany, and held academic positions at the Medical Faculties of the Universities of Freiburg and Heidelberg until 1998.


Dr. Jian Cao

Dr. Jian Cao

Dr. Jian CaoWith multidiscipline knowledge in Accounting & Finances at Tianjin University of Commerce (BSc), Computer Science at University of Birmingham (MSc) and Mechanical Engineering at University of Birmingham (PhD), Jian Cao founded RTC Innovation Ltd in 2009 and plays leading roles in technology transfer, technology-based spin-out. Before establishing RTC Innovation, Jian worked as research fellow at the University of Birmingham for a European Union FP6 Integrated Project on Mass-Manufacture of Miniature/Micro Products, cooperated with EMPA, Switzerland. Jian has been involved in research work since 2002, for Corus, UK, Israel Aircraft Industries, IMRA, Japan, Shougang Research Institute of Technology, China etc. In 1998, Jian worked as senior accountant in China Aerospace Science and Technology Corporation after graduated from his first degree in China.Jian has made and led in two venture capital investments recently, and sits on the boards as directors of the following two companies: Oxford Multi Spectral Ltd and Oxford Vacmedix HK ltd.


Ray Barlow

Ray Barlow

Ray Barlow is currently a deal lead in Amgen’s Strategy and Corporate Development team. In his Role, Ray has special responsibility for Amgen’s European business.

Ray has experience in deal making in large Pharma, public and private biotechnology companies, start-up environments and as the owner of his own businessRay has negotiated and closed all types of agreements, including: acquisition, equity investment, out-licensing, in-licensing, (co)development, (co)marketing, (co)promotion, option, supply, quality, manufacturing and IP assignment agreementsRay started his career with AstraZeneca transitioning from R&D into Corporate Business Development at the London HQ over an 11-year period.

During 6 years of Corporate Development, Ray was responsible for a number of externalization and regional expansion projects (including China and Russia/CEE), as well as acquisition and licensing projects in multiple Therapy Areas.

Ray then became Regional Business Director for Central and Eastern Europe and Russia, where he managed a regional team responsible for delivering a contribution of ca. $200M from 14 products in 14 countries.

After 11 years at AstraZeneca, Ray joined the sell-side of the industry and became Head of Business Development for the private company Microscience Ltd, which was sold to Emergent BioSolutions Inc. Ray was appointed VP of BD for Emergent and, in addition to number of completed licensing deals, he was also involved in the listing of Emergent on NASDAQ.

In July 2006, Ray set up his own business “BD Solutions Ltd”, which specialized in all aspects of Corporate and Business Development. He advised a range of clients (ranging from Japanese majors to University start-ups) from diverse geographies on corporate development and country entry projects. Ray also worked on fundraising for start-up companies as interim CEO.

In April 2010, Ray joined Crucell NV in the Netherlands and was one of the senior BD team that was involved with the sale of Crucell for $2.3Bn to Johnson & Johnson in Q1 2011.

Post acquisition, Ray took on responsibility for all different BD activities for immunotherapy-based deals for Crucell/J&J. As part of this he had special responsibility for strategic investments and relationships in Taiwan and Australia.

Ray joined Amgen on June 1st 2012. He is based in Zug, Switzerland.

Ray has a PhD in Chemistry (summa cum laude) from Manchester University, UK and a MBA with distinction form the Manchester Business School, UK.


Przemysław Walasek

Przemysław Walasek

Przemysław Walasek graduated from the European University of Viadrina in Frankfurt (Oder) and Adam Mickiewicz University in Poznan.

He is responsible for Intellectual Property in Taylor Wessing e|n|w|c.

He has extensive experience in advising clients regarding all legal aspects of e-business, new technologies, copyrights, including entrepreneurs specialising in on-line. He represents clients in cases regarding internet domains and breaches in coded TV security systems. He has taken part in many internet start-ups and advised entrepreneurs on copyrights fees to organisations. He also provides legal services regarding commercial transactions and supports relevant corporate issues.

He specialises in copyrights, e-business and corporate issues.

He is not only an author of various publications regarding Intellectual Property Law, IT and e-business but also Przemek is a lecturer at many relevant and topical conferences.He has an excellent command of both German and English


Charles Bridgen

Charles Bridgen

Charles Bridgen is the European Business Development & Licensing Director for Amgen International. In this role he has supported many of Amgen’s recent global M&A transactions including the $1.16B acquisition of Micromet, a biotechnology company founded in Germany and the acquisition of Mustafa Nevzat Pharmaceuticals, a privately held Turkish company. He is also responsible for external R&D partnerships in Europe including Eastern Europe and Russia.Having joined Amgen in 2004 as Therapeutic Area Lead for Oncology, his most recent role was Executive Medical Director for the UK & Ireland where he led Amgen’s R&D efforts in this region. Prior to joining Amgen, Charles worked for Eli Lilly & Company as a Clinical Research Physician. Before joining industry, Charles trained as a surgeon in the UK’s National Health Service working in academic teaching hospitals in London. He is a Fellow of the Royal College of Surgeons in England, a Member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and holds an MBA from Columbia & London Business Schools.


 

Klaus Martin

Klaus Martin is the Senior Director of Polpharma Biologics leading its global business and product and development activities. With his broad experience in strategy and development of Biosimilars and Biobetters. Klaus joined Polpharma to set up its Biologics business in October 2010. Prior to Polpharma, for eight years he held global management positions at Sandoz Biopharmaceuticals, first as Development Project Leader, e.g. for Sandoz’ filgrastim and, a.i. for their rituximab biosimilars, then as Head of Global Pre-clinical and Clinical development and finally as Head of BD&L and Portfolio Management as a member of the Biopharmaceuticals Executive Committee. His teams helped bring to the market Sandoz’ first three biosimilars in the EU, US and Japan.Klaus is a biochemist by training and holds a PhD in Pathology from the University of Cambridge. Before joining the pharmaceutical industry, he spent three years as a strategy consultant with OC&C advising international clients in a variety of industries.


Bill Mason

Bill Mason

Dr. Bill Mason is an Executive Director of the Sage Group based in USA and Europe. He is also a non-executive Chairman or Board Director of several EU and US high technology private and/or publicly quoted (UK and US) companies in healthcare and biosciences. He has considerable experience in the public and private sectors, spanning the successful strategic and commercial development and value realization of high technology life science- and healthcare- focused industries. These include pharmaceutical, biotechnology, medical technology and diagnostics companies, where he has worked with private equity and institutional investors, VC funds and corporate finance firms in the life science and health care domains.Dr. Mason has a strong history of founding, funding, developing, turning around and exiting from a number of companies in this space, as well as working with well-established, more mature companies. He has considerable experience of commercial development of healthcare businesses, in respect of sales and marketing and distribution routes to relevant markets, as well as the regulatory requirements to take programs to commercial realization.He has led and been actively involved with a number of IPOs and secondary fundings (including PIPEs) in public markets (LSE, NASDAQ) in addition to numerous funding activities for private equity companies. Dr. Mason has strong management, transactional and financing experience with both private equity- and publicly- funded companies. He is a highly motivated and organized individual with a good track record in developing innovative advanced technology businesses, and realizing shareholder value via trade sale or flotation, having been involved in more than 75 M&A, licensing deals and financings.


Stephen Rhind

Stephen Rhind

Stephen Rhind is a Commercial Consultant at ProPharma Partners Ltd. He has around 30 years of experience in the pharma-biotech sector, spanning Europe, the US and Asia. As a current consultant he has a number of Asian Clients in Singapore as well as working independently as a consultant for a Tokyo based portfolio company of Mitsui & Co., Global Investment Ltd.

Previously Stephen has spent nearly 7 years in Asia. As Senior Vice President, Corporate Development at S*BIO Pte Ltd, he was responsible for playing a significant role in the execution of 2 major deals totalling in excess of $660m and which received a peer reviewed industry award for the most successful bio-partnership in Asia in 2009. In these deals upfronts and related payments of more than $45m were received. Additionally he has supported the CEO of S*BIO Pte Ltd in the raising of $60m of private finance.

Stephen obtained his PhD in Biochemistry from Cambridge University having entered the biotech industry in 1983 and has worked in 3 public and 1 private biopharmaceutical companies.


Ferenc Marofka

Ferenc Marofka

Project Officer – European Commission, DG Research & InnovationFerenc is a Project Officer at DG Research & Innovation, in the Health Directorate. He manages calls and monitors the subsequent projects in the domain of health research with a focus on advanced therapies and systems medicine. He also contributes to EU’s health research policy in the fields of innovation, SMEs and underperformance of new member states.Ferenc holds a degree in economics and followed courses in medicine as well. Prior to joining the European Commission in 2008, he worked for Hungarian SMEs in the pharma sector. His career at the Commission started in DG Internal Market and he has moved to health research in 2012.


Kåre Riis Nielsen

Kåre Riis Nielsen

Kåre Riis Nielsen is Director of European Affairs. Kåre is responsible for Novozymes’ public affairs and media relations in Europe. He joined Novozymes in 2009. Prior to that he has been an independent consultant and held positions in the World Bank, United Nations and the Nordic Council of Ministers.


Krzysztof Senger

Krzysztof Senger

Senior Manager in R&D and Government Incentives PolandKrzysztof has over 11 years of professional experience in advising public authorities and private companies in course of implementation of the EU funds and financial instruments. Krzysztof specializes in cost benefit analysis, feasibility studies, preparation of project documentation for large infrastructure projects (mainly R&D). He has been raising funds for investments, research and human resources development and has been also involved in conducting negotiations with the European Commission, cooperation with the European Investment Bank and the Jaspers Initiative.


Michał Jasiorkowski

Michał Jasiorkowski

Michał Jasiorkowski works in National Center for Research and Development, where he is responsible for designing and implementation of new types of public-private investment programs, which currently comprise: BRIdge VC (program run jointly with leading Polish and foreign VC funds), BRIdge Mentor (program run jointly with leading consulting companies) and BRIdge α (set of investment vehicles for early-stage R&D Project).Michał has over 11 years professional experience gained in both public and private sector. He is also Certified Information Systems Auditor (CISA), as well as graduate of Cracow University of Economics and Warsaw School of Economics.


Michał Bańka

Michał Bańka

Michał Bańka worked at the Ministry of Economy to manage and mediate implementation of several EU funded programs. Since 2006 his responsibilities have included running the financial departments of three Programs: (1) Improving the Competitiveness of Enterprises, (2) Innovative Economy and (3) Infrastructure and Environment. He has held the positions of Deputy Director, and from 2012 Director of the Department of Business Environment Institution Support of the Polish Agency for Enterprise Development. His responsibilities include: (1) Providing support for business incubators in finding innovative ideas and capital input for “Start-ups”, (2) Support of the ‘Business Angels’ Network, (3) Support for Business Environment Institutions, (4)

Originator, Loan fund managers for micro and small enterprises with the participation of business angel or venture capital fund.

Financing of advisory services that are necessary to attract external investors. His business career is combined with an academic role involving teaching at the Faculty of Political Science at Warsaw University. He is the project manager and general executive of R & D projects of the Ministry of Science and Higher Education and author and co-author of several monographs and scientific articles.